Showing 1 - 10 of 11 Neurodegenerative Diseases

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Nilene Crisci

Phone: 713.441.3771

To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verif ... Read more >

Status: Enrolling

Investigator: Jason Thonhoff

Study Coordinator: Anjana Singh

Phone: 713.441.9120

In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. We completed a phase 1 study of infusions of expanded autologous Tregs in combina ... Read more >

Status: Enrolling

Investigator: Tetsuo Ashizawa

Study Coordinator: Valerie Flores

Phone: 713.363.9803

The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA). ... Read more >

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: Aramide Balogun

Phone: 713.441.6947

The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >

Status: Enrolling

Investigator: Jason Thonhoff

Study Coordinator: Aramide Balogun

Phone: 713.441.6947

This leukapheresis study proposes to continue our work in developing and optimizing our Treg manufacturing process. Under this study, up to 10 patients with ALS will undergo leukapheresis. Their Tregs will subsequently be isolated and expand ... Read more >

Status: Open Not Enrolling

Investigator: Sherif Nagueh

Study Coordinator: Nirali Patel

Phone: 713.441.2116

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting ... Read more >

Status: Enrolling

Investigator: Maria Pascual

Study Coordinator: Victoria Arbones

Phone: 713.441.7650

The ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohor ... Read more >

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator: Anjana Singh

Phone: 713.441.9120

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. ... Read more >

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Anjana Singh

Phone: 713.441.9120

Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that ... Read more >

Status: Open Not Enrolling

Investigator: Jun Li

Study Coordinator: Anjana Singh

Phone: 713.441.9120

This study aims to look at the genetic differences between individuals with neurological disorders and healthy controls, and whether these genetic differences contribute to nerve conduction speeds. We expect that this study will identify a small ... Read more >

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Nilene Crisci

Phone: 713.441.3771

The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is ... Read more >